Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYFE23)

Drug Name
SB-206343 Drug Info
Synonyms
SB206343; CHEMBL326473; 2-[(1R,3S,4S)-1-BENZYL-4-[N-(BENZYLOXYCARBONYL)-L-VALYL]AMINO-3-PHENYLPENTYL]-4(5)-(2-METHYLPROPIONYL)IMIDAZOLE; RUN; SB-206343; 1hps; SB 206343; AC1L9J53; SCHEMBL13987202; BDBM50037121; N-{(1S,2S,4R)-1-benzyl-2-hydroxy-4-[5-(2-methylpropanoyl)-1H-imidazol-2-yl]-5-phenylpentyl}-N~2~-[(benzyloxy)carbonyl]-L-valinamide; {(S)-1-[(1S,2S,4R)-1-Benzyl-2-hydroxy-4-(5-isobutyryl-1H-imidazol-2-yl)-5-phenyl-pentylcarbamoyl]-2-methyl-propyl}-carbamic acid benzyl ester; benzyl N-[(2S)-1-[[(2S,3S,5R)-3-hydro
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus-1 infection 1C62 Terminated [1]
Cross-matching ID
PubChem CID
446120
TTD Drug ID
DMYFE23

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Human immunodeficiency virus Protease (HIV PR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Saquinavir DMG814N Human immunodeficiency virus infection 1C62 Approved [3]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [4]
Ritonavir DMU764S Human immunodeficiency virus infection 1C62 Approved [5]
Atazanavir DMSYRBX Human immunodeficiency virus infection 1C62 Approved [6]
Amprenavir DMLMXE0 Human immunodeficiency virus infection 1C62 Approved [7]
Darunavir DMN3GCH Human immunodeficiency virus infection 1C62 Approved [8]
Tipranavir DM8HJX6 Human immunodeficiency virus infection 1C62 Approved [9]
Fosamprenavir DM4W9B3 Human immunodeficiency virus infection 1C62 Approved [10]
BI 201335 DM3MXT8 Hepatitis C virus infection 1E51.1 Phase 3 [11]
BMS 650032 DMQI43G Hepatitis C virus infection 1E51.1 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Protease (HIV PR) TT5FNQT POL_HV1B1 Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005565)
2 Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'--P2' amide bond isostere. J Med Chem. 1994 Sep 16;37(19):3100-7.
3 PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008 Dec;80(12):2053-63.
4 Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liq... J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):575-80.
5 Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009 Apr;33(4):307-20.
6 Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacod... J Infect Dis. 2001 Apr 1;183(7):1126-9.
7 Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503.
8 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in ... J Antimicrob Chemother. 2009 Aug;64(2):398-410.
11 2011 Pipeline of Boehringer Ingelheim Pharma.
12 2011 Pipeline of Bristol-Myers Squibb.